Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT05561348 Recruiting - Parkinson Disease Clinical Trials

The Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Impairments in Early-stage PD

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study is a double blind comparative study examining the effectiveness of the transcutaneous auricular vagus nerve stimulation treatment on early-stage Parkinson's disease patients . We hypothesize that treatment using transcutaneous auricular vagus nerve stimulation will improve gait impairments and cortical activity in early-stage Parkinson's disease patients.

NCT ID: NCT05558787 Not yet recruiting - Parkinson Disease Clinical Trials

AADC/TDC in Advanced Parkinson's Disease

Start date: September 2022
Phase:
Study type: Observational

Rationale: Many persons with Parkinson's disease (PD) develop a progressive resistance to levodopa, which is the pharmacological mainstay of PD treatment. Recently, two enzymatic pathways have been identified that could be (partially) responsible for this: 1) breakdown of levodopa by bacterial tyrosine decarboxylase (TDC), an enzyme which normally decarboxylates dietary tyrosine but which is also able to decarboxylate levodopa. Accumulation of bacterial TDC in the small intestine, such as in the context of small-intestinal bacterial overgrowth (SIBO) - for which persons with PD are at increased risk - has the potential to prematurely metabolize levodopa, hence limiting its bioavailability and effect. 2) paradoxical induction of activity of the enzyme aromatic L-amino acid decarboxylase (AADC) in chronic users of levodopa combined with a peripheral decarboxylase inhibitor, also leading to a premature breakdown of levodopa and limitation of its bioavailability and effect. Primary objective: in a cross-sectional sample of advanced (≥5 years) Parkinson's disease determining the prevalence of increased bacterial TDC activity in feces, and the prevalence of increased AADC activity in serum. Secondary objective: correlating these biomarkers to clinical parameters, correlating composition of the microbiome to TDC activity, to the presence of levodopa resistance, and to factors related to socio-economic status. Study design: using feces, serum samples and clinical data from n=50 participants, the relevant enzymes' activity will be measured and the composition of the gut microbiome will be determined. These will be correlated to the clinical and demographic parameters.

NCT ID: NCT05558189 Not yet recruiting - Parkinson Disease Clinical Trials

Vibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients

Start date: November 20, 2022
Phase: N/A
Study type: Interventional

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on refractory post surgery PD. VCR will be administered with a device called the vibrotactile axon Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as levodopa and or deep brain stimulation. Patients will be followed for two years.

NCT ID: NCT05557864 Recruiting - Parkinson's Disease Clinical Trials

Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease

Start date: August 25, 2016
Phase: N/A
Study type: Interventional

This protocol will characterize the effects of deep brain stimulation (DBS) location (both adverse and beneficial) on motor signs in people with Parkinson's disease (PD). This information can be used to inform future DBS protocols to tailor stimulation to the specific needs of a patient. If targeted dorsal GP stimulation is shown to significantly improve motor features that are typically resistant to dopamine replacement therapy, these experiments will likely have major impact on clinical practice by providing a potential strategy to these medically intractable symptoms.

NCT ID: NCT05556993 Recruiting - Parkinson Disease Clinical Trials

Parkinson's Research With Inclusion, Diversity and Equity

PRIDE
Start date: June 29, 2022
Phase:
Study type: Observational

The purpose of this study is to identify the health and healthcare needs of LGBTQIA+ and non LGBTQIA+ communities living with Parkinson's disease.

NCT ID: NCT05551377 Not yet recruiting - Parkinson Disease Clinical Trials

Head-up Tilt Sleeping to Alleviate Orthostatic Hypotension, Supine Hypertension and Nocturia in Parkinson's Disease

Start date: September 2022
Phase: N/A
Study type: Interventional

Autonomic dysfunction is common and often underrecognized in Parkinson's disease (PD). Orthostatic hypotension (OH) affects up to a third of PD patients and often coincides with supine hypertension. This co-occurrence complicates pharmacological treatment as treatment of one can negatively affect the other. Head-up tilt sleeping (HUTS) could improve both. This phase II randomized controlled trial (RCT) aims to investigate the efficacy and tolerability of this understudied intervention, leading to optimal implementation strategies.

NCT ID: NCT05551338 Recruiting - Parkinson Disease Clinical Trials

Serious Games for Parkinson's Disease

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

IMPORTANCE: Rehabilitation games have been shown to improve cognitive function among people with various disorders but they have not been explored in home settings for patients with Parkinson's disease. OBJECTIVE: To collect pilot data regarding the therapeutic benefits of self-administered rehabilitation games among patients with Parkinson's disease. METHODS: The investigators will recruit 20 patients with Parkinson's disease into a pilot randomized controlled trial. Patients will be asked to perform two 30-minute sessions per week of training using serious games over a 3-month period in addition to conventional care or undergo only usual care. Patients will be evaluated at baseline, after 12 weeks of treatment, and at 24 weeks. Improvements in cognitive function, depression, quality of life, and mobility will be assessed. RELEVANCE: Identifying whether self-administered rehabilitation games can lead to clinical improvements could have significant implications for the management of the disease.

NCT ID: NCT05550714 Not yet recruiting - Dexmedetomidine Clinical Trials

Choice of Anaesthesia in Microelectrode Recording-Guided Deep-Brain Stimulation for Parkinson's Disease(CHAMPION)

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Subthalamic nucleus(STN)-deep brain stimulation(DBS) under general anesthesia has been applied to PD patients who can not tolerate awake surgery, but general anesthesia will affect the electrical signal in microelectrode recording(MER) to some degrees. This study is a prospective randomized controlled, non-inferiority study, open label, endpoint outcome evaluator blinded, two-arm study. Parkinson's disease patients undergoing STN- DBS are randomly divided into conscious sedation group (dexmedetomidine) and general anesthesia group (desflurane). Normalized root mean square (NRMS) is used to compare the difference of neuronal activity between the two groups. The primary outcome is the percentage of high-NRMS recorded by MER signal (with the average NRMS recorded by MER after entering STN greater than 2.0). The secondary outcomes are the NRMS, lengths of STN, the numbers of MER tracks, the differences of clinical outcomes 6 months after operation.etc.

NCT ID: NCT05545826 Not yet recruiting - Parkinson Disease Clinical Trials

VCR: A Treatment for Early Stage Parkinson's Disease

Start date: October 20, 2022
Phase: N/A
Study type: Interventional

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on early stage Parkinson's symptoms. VCR will be administered with a device called the vibrotactile axon Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as levodopa and or deep brain stimulation. Patients will be followed for two years.

NCT ID: NCT05544305 Not yet recruiting - Parkinson Disease Clinical Trials

Digitised Home Based Care for Parkinson's Disease

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Parkinson's disease is the world's fastest-growing neurological condition. It is a progressive neurodegenerative disorder that causes a wide range of movement-related (motor) problems (slowness, stiffness, tremor, balance difficulties) and non-motor problems (disturbances of thinking, memory, perception, mood, bladder, bowels, blood pressure). Even before the pandemic, NHS services were struggling to meet the demand for care. To address this need for support, the investigators have co-designed an innovative digital care pathway, Home Based Care (HBC), with people with Parkinson's (PwP) and care partners (CP) to deliver self-management support and clinical expertise to the patient's home. This pathway is supported by remote monitoring with a wrist-worn sensor and questionnaires. In this study, the investigators will be digitising this pathway so that data from a variety of sources (including the sensor, questionnaires, and patients' health records) can be combined in one place to enable more personalised care and to provide advice to support self-management of symptoms by patients. After the investigators have set up the digitised pathway, its implementation will be evaluated with a group of 120 people with Parkinson's and their care partners and associated healthcare providers through the Plymouth Parkinson's Service. The investigators will examine participants' adoption of and engagement with the patient-facing digital platform over the course of 3 months and gather their feedback about its usability and acceptability. A smaller group of the participants will discuss their experiences in more detail to help pinpoint aspects that work well and those needing adjustment and development. The investigators anticipate that this system will result in improved quality of life and care and increased knowledge and confidence for self-managing symptoms. The results of the study will be used to improve the digitised Home Based Care pathway. People with Parkinson's and care partners involved in the project will help guide the sharing of these results with healthcare providers and the general public.